Lantheus Medical Imaging Boston Consulting Group Matrix
See the Bigger Picture
Lantheus Medical Imaging’s BCG Matrix preview teases where its portfolio lands—high-growth stars, steady cash cows, risky dogs, or opportunistic question marks—and what that means for your capital and R&D bets. Want the full picture with exact quadrant placements, data-backed recommendations, and tactical moves tailored to Lantheus’s market dynamics? Purchase the complete BCG Matrix for a polished Word report plus an editable Excel summary you can act on now. Skip the guesswork—get clarity and a clear path to smarter investment decisions.
Stars
PYLARIFY PSMA PET leadership
PYLARIFY, FDA-approved for PSMA PET in 2021, holds a leading share in a rapidly expanding PSMA PET market driven by prostate cancer care adoption; Lantheus reported Pylarify net product sales of ~$300M in 2023, reflecting strong clinical pull.
Growth-stage position consumes cash for distribution, education, and site onboarding, but unit economics improve with volume and reimbursement, converting spend into higher throughput.
Maintain investment to defend share and expand indications; clear runway exists to mature into a cash cow as market growth normalizes and per-patient volumes stabilize.
Oncology theranostics momentum
Integrated diagnostic-to-therapy oncology theranostics are scaling rapidly, propelled by post-2022 radioligand approvals like lutetium-177 agents; Lantheus sits in the slipstream with targeted agents and partnerships, capturing high-growth demand. Phase III oncology trials commonly exceed $100 million and require large-scale manufacturing and market-access spend. Investing now is justified while leadership is within reach.
AI-enabled imaging analytics
Clinical demand for PET decision support is rising rapidly, with the global PET imaging market projected to grow at ~6% CAGR through 2028, boosting need for AI-enabled analytics. Early-mover advantage can lock in clinical workflows and reimbursement pathways, creating sticky adoption. This requires sustained investment in validation, EHR integration, and payer wins. If uptake stays strong, AI imaging could become a durable profit engine for Lantheus.
Global PET network build-out
Global PET network build-out expands cyclotron and dose distribution coverage, driving share in emerging PET markets as Lantheus scales capacity in 2024; capital intensity is high but the network widens the competitive moat.
As utilization scales, unit economics improve materially, lowering per-dose cost and boosting margin leverage; continue footprint expansion while competitors remain patchy.
- Tag: capital-intensive
- Tag: moat expansion
- Tag: improving unit economics
- Tag: aggressive footprint push
Prostate cancer ecosystem strength
Lantheus sits centrally in the expanding prostate cancer detection-to-monitoring segment, with 2024 channel traction and strong KOL advocacy driving high market visibility. The franchise still needs intensified promotion and real-world data to cement leadership. Successful execution should convert growth into step-down capex and cash‑cow margins.
- Market role: Star
- Gaps: promo + RWD
- Prize: lower capex, higher margins
PSMA PET - scale network & AI to defend share, convert $300M asset
PYLARIFY led PSMA PET with Lantheus net product sales ~300M in 2023; franchise is high-growth (global PET market ~6% CAGR to 2028) and capital‑intensive. Scaling network and AI analytics improves unit economics; Phase III theranostic trials often exceed $100M. Maintain investment to defend share and convert to cash cow as utilization and reimbursement mature.
| Metric | Value |
|---|---|
| Pylarify sales (2023) | ~$300M |
| PET market CAGR | ~6% to 2028 |
| Typical Phase III cost | >$100M |
What is included in the product
Detailed Word Document
Concise BCG review of Lantheus: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing each Lantheus unit in a quadrant — clean, export-ready for C-level decks and drag-drop into PowerPoint.
Cash Cows
DEFINITY cardiac ultrasound contrast
DEFINITY has a large installed base in over 2,500 hospitals, supporting stable cardiology demand and driving gross margins near 60%, making it a low-growth, high-share cash generator for Lantheus. Incremental investments target manufacturing efficiency and supply reliability to protect volume. Cash flow from DEFINITY funds PET and theranostics R&D and capacity expansion.
TechneLite Tc-99m generators
TechneLite Tc-99m generators sit in a mature market with entrenched multi‑year hospital and clinic contracts and predictable weekly generator reloads, supporting steady utilization; Tc-99m remains used in roughly 80% of diagnostic nuclear medicine procedures. Pricing power is limited, yet operational excellence and high uptime drive strong cash conversion without heavy promotion. Focus on reliability and harvest cash flows.
Legacy cardiac SPECT tracers
Legacy cardiac SPECT tracers like Cardiolite deliver steady, modest demand and require minimal marketing; distribution is streamlined through established hospital/radiology channels. They sustain healthy gross margins from scale and familiarity, comprising a low-double-digit percent of Lantheus’ 2023 revenue ($691.8M). Proceeds are redeployed into high-growth oncology assets such as PSMA imaging.
Service and distribution infrastructure
Service and distribution infrastructure provides steady radiopharmacy logistics that underpin recurring revenue; as of 2024 these operations remain the primary cash generator while end-market growth is modest, allowing the platform to throw off free cash flow that funds higher-risk R&D.
- Low market growth, high cash generation
- Small capex lifts throughput and margin
- Stable logistics quietly funds pipeline risk
Long-standing hospital contracts
Long-standing hospital contracts deliver high renewal rates and sticky relationships for Lantheus, keeping acquisition costs per order low and payouts stable; optimization of supply, billing and service beats splashy marketing to protect margin.
Preserve contract terms, focus on efficiency gains and service-level KPIs to keep cash coming and limit churn risk amid pricing pressures.
Contrast agents and Tc-99m generators — cash engines with 60% margins
DEFINITY (installed base >2,500 hospitals) and TechneLite Tc-99m generators (Tc-99m ~80% of diagnostic NM) are Lantheus cash cows, driving gross margins near 60% and steady cash conversion; legacy cardiac tracers = low-double-digit % of 2023 revenue ($691.8M). Operations and service logistics fund PET/theranostics R&D while focus stays on efficiency and contract retention.
| Product | Role | Key metrics |
|---|---|---|
| DEFINITY | Cash generator | >2,500 hospitals; ~60% gross margin |
| TechneLite Tc-99m | Stable cash flow | Tc-99m ~80% NM use; predictable reloads |
| Cardiolite/legacy | Steady revenue | Low-double-digit % of 2023 rev ($691.8M) |
Delivered as Shown
Lantheus Medical Imaging BCG Matrix
The Lantheus Medical Imaging BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no demo content—just the fully formatted, analysis-ready report tailored for medical imaging strategy. Once bought, the clean, editable document is delivered instantly to your inbox. Use it straightaway in presentations, planning sessions, or investor decks with zero surprises.
See the Bigger Picture
Lantheus Medical Imaging’s BCG Matrix preview teases where its portfolio lands—high-growth stars, steady cash cows, risky dogs, or opportunistic question marks—and what that means for your capital and R&D bets. Want the full picture with exact quadrant placements, data-backed recommendations, and tactical moves tailored to Lantheus’s market dynamics? Purchase the complete BCG Matrix for a polished Word report plus an editable Excel summary you can act on now. Skip the guesswork—get clarity and a clear path to smarter investment decisions.
Stars
PYLARIFY PSMA PET leadership
PYLARIFY, FDA-approved for PSMA PET in 2021, holds a leading share in a rapidly expanding PSMA PET market driven by prostate cancer care adoption; Lantheus reported Pylarify net product sales of ~$300M in 2023, reflecting strong clinical pull.
Growth-stage position consumes cash for distribution, education, and site onboarding, but unit economics improve with volume and reimbursement, converting spend into higher throughput.
Maintain investment to defend share and expand indications; clear runway exists to mature into a cash cow as market growth normalizes and per-patient volumes stabilize.
Oncology theranostics momentum
Integrated diagnostic-to-therapy oncology theranostics are scaling rapidly, propelled by post-2022 radioligand approvals like lutetium-177 agents; Lantheus sits in the slipstream with targeted agents and partnerships, capturing high-growth demand. Phase III oncology trials commonly exceed $100 million and require large-scale manufacturing and market-access spend. Investing now is justified while leadership is within reach.
AI-enabled imaging analytics
Clinical demand for PET decision support is rising rapidly, with the global PET imaging market projected to grow at ~6% CAGR through 2028, boosting need for AI-enabled analytics. Early-mover advantage can lock in clinical workflows and reimbursement pathways, creating sticky adoption. This requires sustained investment in validation, EHR integration, and payer wins. If uptake stays strong, AI imaging could become a durable profit engine for Lantheus.
Global PET network build-out
Global PET network build-out expands cyclotron and dose distribution coverage, driving share in emerging PET markets as Lantheus scales capacity in 2024; capital intensity is high but the network widens the competitive moat.
As utilization scales, unit economics improve materially, lowering per-dose cost and boosting margin leverage; continue footprint expansion while competitors remain patchy.
- Tag: capital-intensive
- Tag: moat expansion
- Tag: improving unit economics
- Tag: aggressive footprint push
Prostate cancer ecosystem strength
Lantheus sits centrally in the expanding prostate cancer detection-to-monitoring segment, with 2024 channel traction and strong KOL advocacy driving high market visibility. The franchise still needs intensified promotion and real-world data to cement leadership. Successful execution should convert growth into step-down capex and cash‑cow margins.
- Market role: Star
- Gaps: promo + RWD
- Prize: lower capex, higher margins
PSMA PET - scale network & AI to defend share, convert $300M asset
PYLARIFY led PSMA PET with Lantheus net product sales ~300M in 2023; franchise is high-growth (global PET market ~6% CAGR to 2028) and capital‑intensive. Scaling network and AI analytics improves unit economics; Phase III theranostic trials often exceed $100M. Maintain investment to defend share and convert to cash cow as utilization and reimbursement mature.
| Metric | Value |
|---|---|
| Pylarify sales (2023) | ~$300M |
| PET market CAGR | ~6% to 2028 |
| Typical Phase III cost | >$100M |
What is included in the product
Detailed Word Document
Concise BCG review of Lantheus: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing each Lantheus unit in a quadrant — clean, export-ready for C-level decks and drag-drop into PowerPoint.
Cash Cows
DEFINITY cardiac ultrasound contrast
DEFINITY has a large installed base in over 2,500 hospitals, supporting stable cardiology demand and driving gross margins near 60%, making it a low-growth, high-share cash generator for Lantheus. Incremental investments target manufacturing efficiency and supply reliability to protect volume. Cash flow from DEFINITY funds PET and theranostics R&D and capacity expansion.
TechneLite Tc-99m generators
TechneLite Tc-99m generators sit in a mature market with entrenched multi‑year hospital and clinic contracts and predictable weekly generator reloads, supporting steady utilization; Tc-99m remains used in roughly 80% of diagnostic nuclear medicine procedures. Pricing power is limited, yet operational excellence and high uptime drive strong cash conversion without heavy promotion. Focus on reliability and harvest cash flows.
Legacy cardiac SPECT tracers
Legacy cardiac SPECT tracers like Cardiolite deliver steady, modest demand and require minimal marketing; distribution is streamlined through established hospital/radiology channels. They sustain healthy gross margins from scale and familiarity, comprising a low-double-digit percent of Lantheus’ 2023 revenue ($691.8M). Proceeds are redeployed into high-growth oncology assets such as PSMA imaging.
Service and distribution infrastructure
Service and distribution infrastructure provides steady radiopharmacy logistics that underpin recurring revenue; as of 2024 these operations remain the primary cash generator while end-market growth is modest, allowing the platform to throw off free cash flow that funds higher-risk R&D.
- Low market growth, high cash generation
- Small capex lifts throughput and margin
- Stable logistics quietly funds pipeline risk
Long-standing hospital contracts
Long-standing hospital contracts deliver high renewal rates and sticky relationships for Lantheus, keeping acquisition costs per order low and payouts stable; optimization of supply, billing and service beats splashy marketing to protect margin.
Preserve contract terms, focus on efficiency gains and service-level KPIs to keep cash coming and limit churn risk amid pricing pressures.
Contrast agents and Tc-99m generators — cash engines with 60% margins
DEFINITY (installed base >2,500 hospitals) and TechneLite Tc-99m generators (Tc-99m ~80% of diagnostic NM) are Lantheus cash cows, driving gross margins near 60% and steady cash conversion; legacy cardiac tracers = low-double-digit % of 2023 revenue ($691.8M). Operations and service logistics fund PET/theranostics R&D while focus stays on efficiency and contract retention.
| Product | Role | Key metrics |
|---|---|---|
| DEFINITY | Cash generator | >2,500 hospitals; ~60% gross margin |
| TechneLite Tc-99m | Stable cash flow | Tc-99m ~80% NM use; predictable reloads |
| Cardiolite/legacy | Steady revenue | Low-double-digit % of 2023 rev ($691.8M) |
Delivered as Shown
Lantheus Medical Imaging BCG Matrix
The Lantheus Medical Imaging BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no demo content—just the fully formatted, analysis-ready report tailored for medical imaging strategy. Once bought, the clean, editable document is delivered instantly to your inbox. Use it straightaway in presentations, planning sessions, or investor decks with zero surprises.
Description
See the Bigger Picture
Lantheus Medical Imaging’s BCG Matrix preview teases where its portfolio lands—high-growth stars, steady cash cows, risky dogs, or opportunistic question marks—and what that means for your capital and R&D bets. Want the full picture with exact quadrant placements, data-backed recommendations, and tactical moves tailored to Lantheus’s market dynamics? Purchase the complete BCG Matrix for a polished Word report plus an editable Excel summary you can act on now. Skip the guesswork—get clarity and a clear path to smarter investment decisions.
Stars
PYLARIFY PSMA PET leadership
PYLARIFY, FDA-approved for PSMA PET in 2021, holds a leading share in a rapidly expanding PSMA PET market driven by prostate cancer care adoption; Lantheus reported Pylarify net product sales of ~$300M in 2023, reflecting strong clinical pull.
Growth-stage position consumes cash for distribution, education, and site onboarding, but unit economics improve with volume and reimbursement, converting spend into higher throughput.
Maintain investment to defend share and expand indications; clear runway exists to mature into a cash cow as market growth normalizes and per-patient volumes stabilize.
Oncology theranostics momentum
Integrated diagnostic-to-therapy oncology theranostics are scaling rapidly, propelled by post-2022 radioligand approvals like lutetium-177 agents; Lantheus sits in the slipstream with targeted agents and partnerships, capturing high-growth demand. Phase III oncology trials commonly exceed $100 million and require large-scale manufacturing and market-access spend. Investing now is justified while leadership is within reach.
AI-enabled imaging analytics
Clinical demand for PET decision support is rising rapidly, with the global PET imaging market projected to grow at ~6% CAGR through 2028, boosting need for AI-enabled analytics. Early-mover advantage can lock in clinical workflows and reimbursement pathways, creating sticky adoption. This requires sustained investment in validation, EHR integration, and payer wins. If uptake stays strong, AI imaging could become a durable profit engine for Lantheus.
Global PET network build-out
Global PET network build-out expands cyclotron and dose distribution coverage, driving share in emerging PET markets as Lantheus scales capacity in 2024; capital intensity is high but the network widens the competitive moat.
As utilization scales, unit economics improve materially, lowering per-dose cost and boosting margin leverage; continue footprint expansion while competitors remain patchy.
- Tag: capital-intensive
- Tag: moat expansion
- Tag: improving unit economics
- Tag: aggressive footprint push
Prostate cancer ecosystem strength
Lantheus sits centrally in the expanding prostate cancer detection-to-monitoring segment, with 2024 channel traction and strong KOL advocacy driving high market visibility. The franchise still needs intensified promotion and real-world data to cement leadership. Successful execution should convert growth into step-down capex and cash‑cow margins.
- Market role: Star
- Gaps: promo + RWD
- Prize: lower capex, higher margins
PSMA PET - scale network & AI to defend share, convert $300M asset
PYLARIFY led PSMA PET with Lantheus net product sales ~300M in 2023; franchise is high-growth (global PET market ~6% CAGR to 2028) and capital‑intensive. Scaling network and AI analytics improves unit economics; Phase III theranostic trials often exceed $100M. Maintain investment to defend share and convert to cash cow as utilization and reimbursement mature.
| Metric | Value |
|---|---|
| Pylarify sales (2023) | ~$300M |
| PET market CAGR | ~6% to 2028 |
| Typical Phase III cost | >$100M |
What is included in the product
Detailed Word Document
Concise BCG review of Lantheus: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing each Lantheus unit in a quadrant — clean, export-ready for C-level decks and drag-drop into PowerPoint.
Cash Cows
DEFINITY cardiac ultrasound contrast
DEFINITY has a large installed base in over 2,500 hospitals, supporting stable cardiology demand and driving gross margins near 60%, making it a low-growth, high-share cash generator for Lantheus. Incremental investments target manufacturing efficiency and supply reliability to protect volume. Cash flow from DEFINITY funds PET and theranostics R&D and capacity expansion.
TechneLite Tc-99m generators
TechneLite Tc-99m generators sit in a mature market with entrenched multi‑year hospital and clinic contracts and predictable weekly generator reloads, supporting steady utilization; Tc-99m remains used in roughly 80% of diagnostic nuclear medicine procedures. Pricing power is limited, yet operational excellence and high uptime drive strong cash conversion without heavy promotion. Focus on reliability and harvest cash flows.
Legacy cardiac SPECT tracers
Legacy cardiac SPECT tracers like Cardiolite deliver steady, modest demand and require minimal marketing; distribution is streamlined through established hospital/radiology channels. They sustain healthy gross margins from scale and familiarity, comprising a low-double-digit percent of Lantheus’ 2023 revenue ($691.8M). Proceeds are redeployed into high-growth oncology assets such as PSMA imaging.
Service and distribution infrastructure
Service and distribution infrastructure provides steady radiopharmacy logistics that underpin recurring revenue; as of 2024 these operations remain the primary cash generator while end-market growth is modest, allowing the platform to throw off free cash flow that funds higher-risk R&D.
- Low market growth, high cash generation
- Small capex lifts throughput and margin
- Stable logistics quietly funds pipeline risk
Long-standing hospital contracts
Long-standing hospital contracts deliver high renewal rates and sticky relationships for Lantheus, keeping acquisition costs per order low and payouts stable; optimization of supply, billing and service beats splashy marketing to protect margin.
Preserve contract terms, focus on efficiency gains and service-level KPIs to keep cash coming and limit churn risk amid pricing pressures.
Contrast agents and Tc-99m generators — cash engines with 60% margins
DEFINITY (installed base >2,500 hospitals) and TechneLite Tc-99m generators (Tc-99m ~80% of diagnostic NM) are Lantheus cash cows, driving gross margins near 60% and steady cash conversion; legacy cardiac tracers = low-double-digit % of 2023 revenue ($691.8M). Operations and service logistics fund PET/theranostics R&D while focus stays on efficiency and contract retention.
| Product | Role | Key metrics |
|---|---|---|
| DEFINITY | Cash generator | >2,500 hospitals; ~60% gross margin |
| TechneLite Tc-99m | Stable cash flow | Tc-99m ~80% NM use; predictable reloads |
| Cardiolite/legacy | Steady revenue | Low-double-digit % of 2023 rev ($691.8M) |
Delivered as Shown
Lantheus Medical Imaging BCG Matrix
The Lantheus Medical Imaging BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no demo content—just the fully formatted, analysis-ready report tailored for medical imaging strategy. Once bought, the clean, editable document is delivered instantly to your inbox. Use it straightaway in presentations, planning sessions, or investor decks with zero surprises.
